Author

R. E. Schwartz

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 4 Immunology· 2 Bioengineering· 1 Cell Biology· 1 Physiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 8 Organism:human· 8 Research Focus:drug response / drug discovery· 4 Research Focus:host-pathogen & immune response· 3 Assay:proteomics· 3 Assay:bulk RNA-seq· 2 Organism:mouse· 2 Approach:statistical model· 2

Frequent Co-Authors

J. L. Johnson· 4 shared S. Chen· 4 shared Y. Bram· 4 shared B. R. tenOever· 3 shared E. R. Kastenhuber· 3 shared L. C. Cantley· 3 shared S. Uhl· 3 shared T. M. Yaron· 3 shared

Activity by Year

2019-2022 · peak 5/yr

Co-Author Collaboration Network

10 top collaborators · 42 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersMicrobiology

J. L. Johnson

Mutual co-authors in cluster

Author profile →

9 papers

Recent·Most cited

Epinephrine inhibits PI3K alpha via the Hippo kinases.

T.-Y. Lin, S. Ramsamooj, K. Liberatore, L. Lantier, N. Vasan, K. Karukurichi, S.-K. Hwang, E. A. Kesicki, E. R. Kastenhuber, T. Wiederhold, T. M. Yaron, M. Zhu, Y. Ma, M. N. Paddock, G. Zhang, , M. D. Goncalves

The paper identifies Hippo kinases as inhibitors of PI3K alpha, showing epinephrine activates these kinases to suppress insulin signaling and glucose metabolism.

bioRxiv · Jul 19, 2022 · PreprintPhysiology

SARS-CoV-2 Infects Syncytiotrophoblast and Activates Inflammatory Responses in the Placenta

L. B. Argueta, L. A. Lacko, Y. Bram, T. Tada, L. Carrau, T. Zhang, S. Uhl, B. C. Lubor, V. Chandar, C. Gil, W. Zhang, B. Dodson, J. Bastiaans, M. Prabhu, C. M. Salvatore, , H. Stuhlmann

This study investigates SARS-CoV-2 infection in placentas from infected pregnant women, finding that the virus infects syncytiotrophoblast cells and triggers maternal immune cell infiltration.

bioRxiv · Jun 1, 2021Cell Biology

Coagulation factors directly cleave SARS-CoV-2 spike and enhance viral entry

E. R. Kastenhuber, J. A. Jaimes, J. L. Johnson, M. Mercadante, F. Muecksch, Y. Weisblum, Y. Bram, R. E. Schwartz, G. R. Whittaker, L. C. Cantley

This study shows coagulation factors like factor Xa and thrombin directly cleave SARS-CoV-2 spike, enhancing viral entry, and suggests anticoagulation could reduce infection.

bioRxiv · Mar 31, 2021Microbiology

Evolution of Antibody Immunity to SARS-CoV-2

C. Gaebler, Z. Wang, J. C. C. Lorenzi, F. Muecksch, S. Finkin, M. Tokuyama, A. Cho, M. Jankovic, D. Schaefer-Babajew, T. Y. Oliveira, M. Cipolla, C. Viant, C. O. Barnes, A. Hurley, M. Turroja, , R. Patel

This study examines the evolution of antibody immunity to SARS-CoV-2 over time, finding that memory B cells evolve with increased potency and resistance to mutations.

bioRxiv · Nov 3, 2020Immunology

The FDA-approved drug Alectinib compromises SARS-CoV-2 nucleocapsid phosphorylation and inhibits viral infection in vitro

T. M. Yaron, B. E. Heaton, T. M. Levy, J. L. Johnson, T. X. Jordan, B. M. Cohen, A. Kerelsky, T.-Y. Lin, K. M. Liberatore, D. K. Bulaon, E. R. Kastenhuber, M. N. Mercadante, K. Shobana-Ganesh, L. He, R. E. Schwartz, , M Kavanagh-Williamson

This study identifies Alectinib as an FDA-approved drug that inhibits SARS-CoV-2 nucleocapsid phosphorylation and viral replication in vitro by targeting host kinases.

bioRxiv · Aug 14, 2020 · PreprintMicrobiology

Identification of Candidate COVID-19 Therapeutics using hPSC-derived Lung Organoids

Y. Han, L. Yang, X. Duan, F. Duan, B. E. Nilsson-Payant, T. M. Yaron, P. Wang, X. Tang, T. Zhang, Z. Zhao, Y. Bram, D. Redmond, S. Houghton, D. Nguyen, D. Xu, , S. Chen

This study uses hPSC-derived lung organoids to identify FDA-approved drugs that inhibit SARS-CoV-2 entry and reduce infection in a model of human COVID-19.

bioRxiv · May 5, 2020 · PreprintMicrobiology

Identification of Drugs Blocking SARS-CoV-2 Infection using Human Pluripotent Stem Cell-derived Colonic Organoids

X. Duan, Y. Han, L. Yang, B. Nilsson, P. Wang, T. Zhang, X. Wang, D. Xu, J. Z. Xiang, s. uhl, Y. Huang, H. Chen, H. Wang, B. R. tenOever, R. E. Schwartz, , T. R. Evans

This study uses human pluripotent stem cell-derived colonic organoids to identify drugs that block SARS-CoV-2 infection, finding mycophenolic acid and quinacrine dihydrochloride effective in vitro and in vivo.

bioRxiv · May 2, 2020 · PreprintMicrobiology

Comparative in vitro transcriptomic analyses of COVID-19 candidate therapy hydroxychloroquine suggest limited immunomodulatory evidence of SARS-CoV-2 host response genes.

M. J. Corley, C. Sugai, M. Schotsaert, R. E. Schwartz, L. C. Ndhlovu

This study examines HCQ's transcriptomic effects in vitro and finds limited overlap with SARS-CoV-2 host response genes, suggesting limited immunomodulatory evidence for HCQ in COVID-19.

bioRxiv · Apr 13, 2020 · PreprintImmunology

Long-Term In Vivo Biocompatibility of Single-Walled Carbon Nanotubes

T. V. Galassi, M. Antman-Passig, Z. Yaari, J. Jessurun, R. E. Schwartz, D. A. Heller

This study evaluates the long-term biocompatibility and biodistribution of single-walled carbon nanotubes in mice after intravenous administration, finding low-level persistence and no adverse effects.

bioRxiv · Dec 9, 2019Bioengineering